Skip to content

Mitochondrial dynamics of levosimendan in the treatment of septic cardiomyopathy

A multicenter, randomized, single-blind, placebo-controlled clinical trial of levosimendan in the prevention and treatment of septic cardiomyopathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065357
Enrollment
Unknown
Registered
2022-11-03
Start date
2022-11-10
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic heart disease

Interventions

control grop:After the initial injection of 0.1 µg/kg/min normal saline for 2-4h, the injection of 0.2 µg/kg/min normal saline for 20-22h was continued
Levosimentan group:After the initial injection of levosimentan at 0.1 µg/kg/min for 2-4h, the injection was continued at 0.2 µg/kg/min for 20-22h

Sponsors

Tianjin Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with sepsis according to the third edition of the International Consensus on Sepsis and Septic Shock; 2. Aged 18 to 80 years; 3. Cardiac index was less than 2.5 L/min/m2 by echocardiography; 4. Dobutamine and levosimendan therapy were required according to hemodynamic parameters.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Previous diagnosis of heart failure or reduced ejection fraction; 3. History of heart valve disease or valve replacement and/or heart stent implantation; 4 Severe pulmonary hypertension and cor pulmonale.

Design outcomes

Primary

MeasureTime frame
Echocardiogram;central venous pressure;Mean arterial blood pressure;

Countries

China

Contacts

Public ContactKeLiang Xie

Tianjin Medical University General Hospital

xiekeliang2009@hotmail.com+86 15332112099

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026